Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Nilotinib
100%
Hematopoietic Cell
83%
Cell Transplantation
83%
Recurrence Free Survival
66%
Survival Rate
50%
Minimal Residual Disease
50%
Liposomal Daunorubicin
16%
Overall Survival
16%
Adverse Event
16%
Spontaneous Remission
16%
Study Subject
16%
Drug Megadose
16%
Vincristine
16%
Cytotoxic Agent
16%
Drug Dose Reduction
16%
Prednisolone
16%
Nursing and Health Professions
Acute Lymphoblastic Leukemia
100%
Nilotinib
100%
Remission
83%
Cell Transplantation
83%
Recurrence Free Survival
66%
Survival Rate
50%
Minimal Residual Disease
50%
Study Subject
16%
Adverse Event
16%
Drug Megadose
16%
Cytotoxic Agent
16%
Drug Dose Reduction
16%
Overall Survival
16%
Vincristine
16%
Prednisolone
16%
Daunorubicin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nilotinib
100%
Acute Lymphoblastic Leukemia
100%
Remission
83%
Recurrence Free Survival
66%
Survival Rate
50%
Minimal Residual Disease
50%
Daunorubicin
16%
Overall Survival
16%
Adverse Event
16%
Cytotoxic Agent
16%
Vincristine
16%
Prednisolone
16%
Biochemistry, Genetics and Molecular Biology
Nilotinib
100%
Cell Transplantation
83%
Hematopoietic Cell
83%
Recurrence Free Survival
66%
Survival Rate
50%
Overall Survival
16%
Drug Megadose
16%
Drug Dose Reduction
16%
Daunorubicin
16%
Glucose-6-Phosphate Dehydrogenase
16%
Prednisolone
16%
Immunology and Microbiology
Cell Transplantation
100%
Hematopoietic Cell
100%
Recurrence Free Survival
80%
Survival Rate
60%
Drug Megadose
20%
Overall Survival
20%
Drug Dose Reduction
20%
Prednisolone
20%